Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 6

1.

17 beta-estradiol and tamoxifen upregulate estrogen receptor beta expression and control podocyte signaling pathways in a model of type 2 diabetes.

Catanuto P, Doublier S, Lupia E, Fornoni A, Berho M, Karl M, Striker GE, Xia X, Elliot S.

Kidney Int. 2009 Jun;75(11):1194-201. doi: 10.1038/ki.2009.69.

3.

The podocyte: a potential therapeutic target in diabetic nephropathy?

Marshall SM.

Curr Pharm Des. 2007;13(26):2713-20. Review.

PMID:
17897015
4.

Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology.

Gruden G, Perin PC, Camussi G.

Curr Diabetes Rev. 2005 Feb;1(1):27-40. Review.

PMID:
18220580
5.

Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy.

Ziyadeh FN, Wolf G.

Curr Diabetes Rev. 2008 Feb;4(1):39-45. Review.

PMID:
18220694
6.

Podocytes: the Weakest Link in Diabetic Kidney Disease?

Lin JS, Susztak K.

Curr Diab Rep. 2016 May;16(5):45. doi: 10.1007/s11892-016-0735-5. Review.

PMID:
27053072
Items per page

Supplemental Content

Support Center